As MIF and D-DT are emerging as disease modifiers in MS, immunopharmacological therapy aimed to target CD74, the transducer of MIF signaling, might be a promising neuroprotective therapy in inhibiting the clinical progression of MS [198,199]. The gene discussed is MIF; the disease is myeloid sarcoma.